Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4869
-0.0290 (-5.62%)
At close: Sep 11, 2026, 4:00 PM EDT
0.4900
+0.0031 (0.64%)
After-hours: Sep 11, 2026, 7:53 PM EDT
Ensysce Biosciences Employees
As of December 31, 2025, Ensysce Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees increased by 2 or 25.00% compared to the previous year.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$450,075
Profits / Employee
-$1,262,390
Market Cap
9.47M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | 2 | 25.00% | 8 | 2 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| CytoMed Therapeutics | 42 |
| Vistagen Therapeutics | 41 |
| Senti Biosciences Holdings | 39 |
| IN8bio | 18 |
| FibroBiologics | 15 |
| Aprea Therapeutics | 8 |
| CNS Pharmaceuticals | 8 |
| Traws Pharma | 7 |
ENSC News
- 11 days ago - Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Accesswire
- 13 days ago - Ensysce completes enrollment for final phase of PF614-MPAR-102 study - TheFly
- 13 days ago - Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study - Accesswire
- 24 days ago - Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium - Accesswire
- 26 days ago - Ensysce Biosciences Transcript: Investor update - Transcripts
- 4 weeks ago - Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Accesswire
- 4 weeks ago - Ensysce Biosciences Earnings release: Q2 2026 - Filings
- 4 weeks ago - Ensysce Biosciences Quarterly report: Q2 2026 - Filings